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Introduction: Ciliated muconodular papillary tumors
(CMPTs) are recently characterized, rare peripheral nodules
of the lung. These small tumors are histologically comprised
of a vaguely organized mixture of nonatypical ciliated
columnar cells, mucous cells, and basal cells, and consis-
tently follow a benign clinical course. However, the histo-
genesis of CMPTs remains uncertain.
Methods: We performed detailed genomic analyses of 10
archived CMPT cases, using next-generation sequencing and
high-resolution melting analysis.
Results: Mutations were identiﬁed in eight of the 10 cases
(80%); four cases harbored the BRAF-V600E mutation, one
case harbored the BRAF-G606R mutation, and three cases
harbored deletions in exon 19 of EGFR. All of the deletions
in EGFR were of the E746-T751/S752V subtype.
Conclusions: The high prevalence of driver gene mutations
in CMPTs supports the notion that these lesions are
neoplastic rather than reactive or metaplastic.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Introduction
Ciliated muconodular papillary tumors (CMPTs) are
rare peripheral nonendobronchial lung nodules thathave recently been characterized. These small nodules
are typically located in the peribronchiolar region, and
exhibit an overall papillary or glandular architecture.
CMPTs consist of a vaguely organized mixture of non-
atypical ciliated columnar cells, mucous cells, and basal
cells, and are typically enveloped with abundant mucus.
Because of the focal stromal destruction and complex
architecture—which includes papillary, micropapillary,
and focally discontinuous lepidic growths—these lesions
may be confused with adenocarcinomas. However,
CMPTs consistently follow a benign clinical course, even
after limited surgery, and an appropriate differential
diagnosis is critical for appropriate patient manage-
ment.1 For example, cilia are not usually observed in
pulmonary adenocarcinoma, and the presence of cilia
and/or terminal plates is one of the most reliable ﬁnd-
ings to support a benign diagnosis.2,3 However, excep-
tional cases of ciliated adenocarcinoma in the lung have
been reported.4Journal of Thoracic Oncology Vol. 11 No. 2: 261-265
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stood. For example, the organized growth pattern and
consistent peribronchiolar localization may indicate a
metaplastic phenomenon. However, the complex archi-
tecture, focal stromal destruction, and autonomous
enlargement that have been observed in a few cases
indicate a neoplastic quality. Therefore, we undertook
next-generation sequencing and high-resolution melting
analyses (HRMA) of 10 well-annotated cases of CMPTs to
clarify their histogenesis.
Methods
Patients and Clinicopathological Analysis
This study was approved by the institutional review
board of the National Cancer Center Hospital (Tokyo,
Japan). A total of 10 CMPT cases were identiﬁed in our
institution between 2006 and 2014. Their clinical and
pathological records were retrospectively reviewed, and
we performed histological analyses of the resected
specimens.
DNA Preparation
We analyzed 10 tumor specimens, including 4 fresh
frozen and 6 formalin-ﬁxed, parafﬁn-embedded (FFPE)
tissue samples. Genomic DNA was extracted from the
fresh frozen tissues using the QIAamp DNA mini Kit
(QIAGEN, Hilden, Germany), and from the FFPE tissues
using the QIAamp DNA FFPE Tissue Kit (QIAGEN). DNA
was quantiﬁed using the Qubit Fluorometer (Life Tech-
nologies, Carlsbad, CA).
Target Deep Sequencing of Mutation Hotspots in
50 Cancer-Related Genes
Ten nanograms of DNA were subjected to library
preparation for the Ion Ampliseq Cancer Hotspot Panel
v2 (Life Technologies), which can detect mutations at
2790 hot spots in 50 cancer-related genes (Table 1). The
library DNAs were prepared by amplifying the targeted
regions using multiplex polymerase chain reaction
(PCR), which was followed by adopter DNA ligation.
Concentrations of the library DNA were evaluated viaTable 1. Cancer Hotspot Panel of 50 Cancer-Related Genes
ABL1 EGFR GNA11 KRAS PTPN11
AKT ERBB2 GNAQ MET RB1
ALK ERBB4 HNF1A MLH1 RET
APC EZH2 HRAS MPL SMAD4
ATM FBXW7 IDH1 NOTCH1 SMARCB1
BRAF FGFR1 IDH2 NPM1 SMO
CDH1 FGFR2 JAK2 NRAS SRC
CDKN2A FGFR3 JAK3 PDGFRA STK11
CSF1R FLT3 KDR PIK3CA TP53
CTNNB1 GNAS KIT PTEN VHLquantitative real-time polymerase chain reaction studies
using the Ion Library Quantitation Kit (Life Technolo-
gies). Sequencing was performed using the Ion Proton
platform (Life Technologies), and mutations were iden-
tiﬁed using Torrent Suite software (Life Technologies).
Conﬁrmatory Analyses
To conﬁrm the BRAF and EGFR mutations, we per-
formed HRMA (Idaho Technology, Salt Lake City, UT),
based on a previously reported method.5 We also per-
formed immunohistochemistry using a monoclonal
antibody to BRAF V600E (1:200 dilution; clone VE1;
Spring Bioscience, Pleasanton, CA), and the results were
estimated separately for each of the three epithelial
components (i.e., ciliated columnar cells, mucous cells,
and basal cells). Cytoplasmic staining was considered a
positive result.
Results
Clinical Findings
Detailed clinicopathological data for the identical 10
cases have been published separately.1 All tumors
showed semiorganized peribronchiolar growth that
consisted of tripartite cellular elements, including cili-
ated columnar cells, mucous cells, and basal cells (Fig. 1).
None of the patients experienced local recurrence or
distant metastasis during a mean follow-up of 43 months
(range, 2–88 months).
Target Deep Sequencing of Mutation Hotspots
We conducted next-generation sequencing at a mean
depth of 2237 (range, 138–12,650) to search for
mutations at hotspots in 50 cancer-related genes fromFigure 1. A representative image of ciliated muconodular
papillary tumors with hematoxylin–eosin staining. The
epithelial components of the lesions consisted of a mixture of
ciliated columnar cells (arrow), mucous cells (asterisk), and
basal cells (arrowhead).
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ber of raw reads per sample was 1,022,275 (range,
447,913–1,910,793), and the mean rate of uniquely
mapped reads was 92.2% (range, 79.0%–95.9%). One or
more mutations were detected in 8 of the 10 cases (80%;
Table 2). The mutated genes consisted of BRAF (50%),
EGFR (30%), PTPN11 (20%), CTNNB1 (10%), IDH1
(10%), and TP53 (10%). The mutations in BRAF were
two types of missense mutations (V600E in four cases
and G606R in one case), and all three EGFR mutations
were the same in frame deletion (delE746-T751/S752V).
All BRAF and EGFR mutations were validated using
HRMA. The BRAF and EGFR mutations were mutually
exclusive among the specimens (Fig. 2).Immunohistochemistry
In the four cases with the BRAF V600E mutation, all
three epithelial components (i.e., ciliated columnar cells,
mucous cells, and basal cells) showed similar cyto-
plasmic staining for BRAF V600E. This ﬁnding suggests
that all 3 elements were neoplastic components (Fig. 3).
As expected, the BRAF V600E–speciﬁc antibody reacted
strongly with the cilia of the columnar cells (the internal
positive control).6
Discussion
In this study, we identiﬁed driver gene mutations in
most CMPTs, and provided evidence that these enigmatic
lesions are indeed neoplastic processes.
Five of the 10 CMPTs (50%) harbored BRAF muta-
tions, including four V600E mutations and one G606R
mutation. Mutations in BRAF are a common driver in
many different types of benign and malignant tumors inTable 2. Gene Mutations Detected in 10 CMPTs
Case No. Age (y) Sex Smoking
Size
(cm)
Tissue
Type
Driver Mut
(Cosmic ID
1 61 F N 0.6 Frozen BRAF-V600E
2 56 M Y 1.1 FFPE BRAF-V600E
3 61 M N 1.0 FFPE BRAF-G606R
4 60 F N 1.5 Frozen EGFR-ex19d
S752V (CO
5 62 F N 1.3 Frozen EGFR-ex19d
S752V (CO
6 66 M N 0.7 FFPE EGFR-ex19d
S752V (CO
7 75 M Y 0.6 FFPE Not detecte
8 57 M Y 1.2 Frozen Not detecte
9 78 M Y 0.9 FFPE BRAF-V600E
10 63 M Y 1.1 FFPE BRAF-V600E
F, female; FFPE, formalin-ﬁxed parafﬁn-embedded specimens; M, malhumans7,8; the most common type is the V600E substi-
tution. BRAF is rarely (3%) mutated in lung adenocar-
cinomas, and this mutation is even rarer (1.3%) among
Asian patients.9 Therefore, the high incidence of BRAF
mutations in CMPTs presents a contrast with the inci-
dence in lung adenocarcinomas. In addition, our histo-
logical ﬁndings exclude a clear relationship between
CMPTs and adenocarcinomas.1 In addition, BRAF-
mutated lung adenocarcinomas typically exhibit aggres-
sive features, such as micropapillary, acinar, and solid
growth patterns, and CMPT-like morphology has not
been documented in our cohort or in a previously re-
ported cohort.9 Moreover, none of our BRAF mutant
CMPTs exhibited worrisome histological ﬁndings.
Similarly, the EGFR mutations in three of our CMPTs
do not necessarily link these lesions to adenocarcinomas.
Although exon 19 deletions (Del-19s) are one of the
most common alterations in lung adenocarcinomas, the
speciﬁc Del-19 that we found in our CMPTs is extremely
rare in lung adenocarcinomas. According to the Somatic
Mutations in EGFR Database, the most frequent Del-19 in
lung adenocarcinomas is delE746-A750 (28.89%), fol-
lowed by delL747-P753insS (2.49%) and delL747-
A750insP (1.73%).10 However, the EGFR deletion in
three of our CMPTs was delE746-T751/S752V, and this
deletion is extremely rare in lung adenocarcinomas (only
one reported case).10 In addition, that particular case
likely did not involve a CMPT, because cilia were not
documented. Therefore, CMPT-like morphology has
never been documented in EGFR-mutated cancers, and
the presence of mucous cells is rare in EGFR-mutated
adenocarcinomas. Moreover, none of the EGFR mutant
CMPTs in our cohort exhibited malignant histological
ﬁndings.ation
) Other Mutations
Mutation
Allele
Frequency
(COSM476) – –
(COSM476) – –
(COSM27640) IDH1-G123R (COSM96922),
CTNNB1-D32N (COSM5672),
and PTPN11-E76K (COSM13000)
6
9
8
el E746-T751/
SM12384)
– –
el E746-T751/
SM12384)
– –
el E746-T751/
SM12384)
PTPN11-P491L (COSM13034) and
TP53-L289F(COSM45446)
16
7
d – –
d – –
(COSM476) Not tested –
(COSM476) Not tested –
e; N, no; Y, yes.
Figure 2. The results of the mutation analyses for 10 ciliated
muconodular papillary tumors.
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ations in CMPTs does not dictate their clinical behavior,
because gene mutations can be present both in benign
and malignant lesions. For example, BRAF mutations
have been found in benign lesions, such as melanocytic
nevi, Langerhans cell histiocytosis, biliary adenomas, and
pilocytic astrocytomas.11,12 In addition, the EGFR muta-
tion has been detected in atypical adenomatous hyper-
plasia.13 However, none of the reported CMPT cases,
including our present series, have metastasized to the
local lymph nodes or distant sites, and none recurred
after surgery. The benign nature of CMPTs is also
implied by the bland cytology, the lack of mitotic ﬁgures,
and the invariable presence of ciliated and basal cell
populations within the tumor. Nevertheless, larger
studies with longer follow-ups are necessary to accu-
rately determine the course of CMPTs.Figure 3. Immunohistochemical analyses of the BRAF-V600E
ciliated muconodular papillary tumors. Each of the three
epithelial components (i.e., ciliated columnar cells, mucous
cells, and basal cells) exhibited cytoplasmic staining for
BRAF-V600E. The monoclonal antibody also strongly cross-
reacted with the cilia of the columnar cells (the internal
positive control).Immunohistochemical analysis with the BRAF V600E–
speciﬁc antibody revealed that all three epithelial com-
ponents (i.e., ciliated cells, mucous cells, and basal cells)
were equally positive for this antibody. This ﬁnding
supports the theory that each of these tripartite elements
constitutes a neoplastic component, at least in these four
CMPTs. This staining also eliminates the remote possi-
bility that ﬂorid metaplastic changes obscured the pres-
ence of a minute BRAF-mutant adenocarcinoma.
Our discovery of BRAF and EGFR mutations in most of
our CMPT cases may also help explain the relationship
between rare benign lesions in the lung. For example,
several groups of researchers have reported unusual
peripheral lung lesions that are histologically similar (if not
identical) to CMPTs, using names such as “solitary periph-
eral ciliated glandular papillomas,” “mucinous adenoma-
tous hyperplasia,” and “peripheral pulmonary papillary/
glandular neoplasms with ciliated cells.”14,15 Similarly, the
histologic features of mixed papillomas resemble those of
CMPTs,2 although these two tumors can be differentiated
by at least their locations (central versus peripheral) and
their associations with the bronchial lumens (endobron-
chial versus nonendobronchial). Therefore,BRAF andEGFR
mutational assays in these benign tumors may clarify their
nosological relationship with CMPTs.
In conclusion, we have identiﬁed frequent driver
mutations of BRAF or EGFR in most of our 10 CMPT
cases. These data support the notion that these lesions
are neoplastic rather than reactive or metaplastic.
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